ASBM/GaBI 2022 biosimilar webinar on biosimilars uptake

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

ASBM/GaBI 2022 biosimilar webinar on biosimilars uptake

Home/Conferences | Posted 26/08/2022 0 Post your comment

ASBM/GaBI Biosimilar Webinar 2022

KEY FACTORS FOR SUCCESSFUL UPTAKE OF BIOSIMILARS: EUROPE AND THE US
Measures taken for improving biosimilar uptake and the potential role of healthcare providers and patients

29 June 2022 | WATCH REPLAY

ASBM 2022 Webinar 1 Banner Square V22G25LT replay

Biosimilars have been in the market for 16 years since its first launch in 2006 in Europe, currently, there are 84 approvals in the EU and 35 in the US, representing almost 90% of the world market. While more biosimilars entering the healthcare system, there remains the need for broader information share and regular discussions to clarify and alleviate the concerns of biosimilars use for physicians and patients, specifically on the issues of prescribing practice and switching of biosimilars.

In this online event, we discussed the key elements contributing to the wide uptake of biosimilars in Europe and the US and physicians’ trust in prescribing and switching of biosimilars. Presentations of concrete examples and experiences on challenges and uptake policies of biosimilars in Europe and the current status of market access of and successful uptake measures implemented for biosimilars in the US allow us to evaluate the role of healthcare providers (physicians, pharmacists) and health policymakers in biosimilars use.

The webinar was held on 29 June 2022 – 10:00 am to 11:50 am EDT.

KEYNOTE SPEAKER:
The Honorary Eric David Hargan, JD, Former United States Deputy Secretary of Health and Human Services

SPEAKERS:
Michael S Reilly, Esq, Executive Director, Alliance for Safe Biologic Medicines
Ralph McKibbin, MD, FACP, FACG, AGAF, Past President of the Pennsylvania Society of Gastroenterology and the Digestive Disease National Coalition
Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP, College of Pharmacy, Ohio State University
Chad Pettit, MBA, Executive Director, Marketing Biosimilars Business Unit, Amgen
Andrew Spiegel, Esq, Executive Director, Global Colon Cancer Association

Panel discussion and Q&A
Steven Stranne, MD, JD, Foley Hoag LLP
The Honorary Eric David Hargan, JD
Michael S Reilly, Esq
Ralph McKibbin, MD, FACP, FACG, AGAF
Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP
Chad Pettit, MBA
Andrew Spiegel, Esq